TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15738933

Group type: EXPERIMENTAL
Intervention: Post-treatment phone contact (experimental group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 20
Study: 12423848

Group type: EXPERIMENTAL
Intervention: Water-soluble gel lubricant
Number of subjects: 8534

Group type: COMPARATOR
Intervention: Water only (control)
Number of subjects: 8534
Study: 10356008

Group type: EXPERIMENTAL
Intervention: Postal prompts sent 2 weeks and 3 months after discharge from hospital.
Number of subjects: 328
Study: 8608893

Group type: COMPARATOR
Intervention: Endoscopic Sclerotherapy (ES)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Transjugular Intrahepatic Portosystemic Shunt (TIPS)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Both TIPS and ES
Number of subjects: 63
Study: 1707221

Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 19

Group type: COMPARATOR
Intervention: Metformin (placebo)
Number of subjects: 19
Study: 6814470

Group type: EXPERIMENTAL
Intervention: Codeine phosphate (30 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Codeine phosphate (60 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: +/--glaucine phosphate (60 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: +/--glaucine phosphate (30 mg)
Number of subjects: 10
Study: 31050927

Group type: EXPERIMENTAL
Intervention: Laser disinfection (LD) group
Number of subjects: 84

Group type: COMPARATOR
Intervention: Pseudo-laser disinfection (PLD) group
Number of subjects: 84
Study: 27392909

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 349

Group type: COMPARATOR
Intervention: Conventional lipid lowering drugs (Group C)
Number of subjects: 349
Study: 24721903

Group type: EXPERIMENTAL
Intervention: Pegylated interferon α (IFNα) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated HDV-infected patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline CD56(dim) NK cells
Number of subjects: 0
Study: 23825402

Group type: EXPERIMENTAL
Intervention: Training on feature difference tasks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training on signal-in-noise tasks
Number of subjects: 0
Study: 21068719

Group type: EXPERIMENTAL
Intervention: Iomazenil (3.7 μg administered intravenously over 10 min)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Iomazenil in healthy controls (n=20)
Number of subjects: 13
Study: 18397193

Group type: EXPERIMENTAL
Intervention: Functional exercise training (supervised by a physical therapist, three times weekly for 4 months)
Number of subjects: 45

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 45
Study: 17450980

Group type: EXPERIMENTAL
Intervention: 10-week, 3 days/week weight-training treatment
Number of subjects: 88

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 88
Study: 15177808

Group type: EXPERIMENTAL
Intervention: Skilled readers naming or making lexical decisions on words and pseudo-words
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Well-compensated dyslexic participant in lexical decision and naming tasks
Number of subjects: 2
Study: 12488953

Group type: EXPERIMENTAL
Intervention: Intravenous glucose tolerance test
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Islet-cell antibody greater than 20 JDFU
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Insulin autoantibodies
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Increasing number of positive autoantibodies
Number of subjects: 52
Study: 9690691

Group type: EXPERIMENTAL
Intervention: Ipsapirone 50 mg once daily
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Ipsapirone 30 mg once daily
Number of subjects: 410

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 410
Study: 7642847

Group type: EXPERIMENTAL
Intervention: Angina-guided medical therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ischemia-guided medical therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coronary revascularization
Number of subjects: 0
Study: 2750268

Group type: EXPERIMENTAL
Intervention: Oral cholera B subunit-whole cell vaccine (BS-WC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Killed whole cell vaccine (WC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference system (Vibrio cholerae Inaba E1 Tor antigenic extract)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Common antigens in vaccines and Vibrionaceae strains
Number of subjects: 0
Study: 1066128

Group type: EXPERIMENTAL
Intervention: Pinkel's modified scheme for ALL with prophylactic irradiation of the CNS
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pinkel's modified scheme for ALL without prophylactic irradiation of the CNS
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Clarkson's scheme for AML with prophylactic irradiation of the CNS
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Clarkson's scheme for AML without prophylactic irradiation of the CNS
Number of subjects: 40
Study: 31299663

Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b eye drops (4 times a day for 3 months)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (bare sclera technique + levofloxacin and 0.1% fluorometholone eye drops 4 times a day for 3 months)
Number of subjects: 53
Study: 28330592

Group type: EXPERIMENTAL
Intervention: twice-weekly deep TMS (dTMS) continuation treatment for up to 12 weeks
Number of subjects: 33
Study: 25956750

Group type: EXPERIMENTAL
Intervention: FOLFOX6 (oxaliplatin, leucovorin, and 5-FU for 12 cycles)
Number of subjects: 408

Group type: COMPARATOR
Intervention: CAPOX (oxaliplatin and capecitabine for eight cycles)
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: FOLFOX6
Number of subjects: 408

Group type: COMPARATOR
Intervention: CAPOX
Number of subjects: 408
Study: 23449691

Group type: EXPERIMENTAL
Intervention: Nonlinear periodized exercise (NLPE) training
Number of subjects: 110

Group type: COMPARATOR
Intervention: Traditional endurance and progressive resistance (EPR) training
Number of subjects: 110
Study: 25427330

Group type: EXPERIMENTAL
Intervention: Total-etch adhesive (Single Bond 2)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Glass-ionomer cement lining + Total-etch adhesive (Single Bond 2)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Self-etching adhesive (Clearfil SE Bond)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Glass-ionomer cement lining + Self-etching adhesive (Clearfil SE Bond)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (no glass-ionomer cement lining)
Number of subjects: 75
Study: 17804473

Group type: EXPERIMENTAL
Intervention: pAKT positive staining in HER2+ tumors
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: pAKT positive staining in HER2- tumors
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: pAKT expression in HER2-/EGFR+ tumors
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: pAKT expression in HER2-/EGFR- tumors
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: Correlation of pAKT with prognosis
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: Predictive value of pAKT for anthracycline resistance
Number of subjects: 823
Study: 16104957

Group type: EXPERIMENTAL
Intervention: Prophy brush with calcium pyrophosphate
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Prophy brush with pumice
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Prophy brush with Nupro coarse
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Prophy brush with Hawe cleanic
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Prophy cup with calcium pyrophosphate
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Prophy cup with pumice
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Prophy cup with Nupro coarse
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Prophy cup with Hawe cleanic
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Pasteless prophy cup
Number of subjects: 72
Study: 11950430

Group type: EXPERIMENTAL
Intervention: Reduced-dose alteplase plus abciximab
Number of subjects: 70

Group type: COMPARATOR
Intervention: Direct angioplasty plus abciximab
Number of subjects: 70
Study: 10226398

Group type: EXPERIMENTAL
Intervention: Chlorpromazine (CPZ) 50 mgs in divided doses with radiation (6000 cGy in six weeks)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (radiation 6000 cGy in six weeks without chlorpromazine)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Chlorpromazine (CPZ) with radiation
Number of subjects: 58
Study: 7893278

Group type: EXPERIMENTAL
Intervention: Herbal remedy Kava-Kava
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Classical homeopathy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary interventions
Number of subjects: 0
Study: 2653876

Group type: EXPERIMENTAL
Intervention: Nifedipine (double dose)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Nifedipine (sublingual)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 178191

Group type: EXPERIMENTAL
Intervention: standard inpatient care
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: brief hospitalization with transitional day care
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: brief hospitalization without transitional day care
Number of subjects: 175
Study: 30092456

Group type: EXPERIMENTAL
Intervention: Multidisciplinary disease management programme with exercise training
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Multidisciplinary disease management programme without exercise training
Number of subjects: 212

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Multidisciplinary disease management programme for patients with contraindications to exercise
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Multidisciplinary disease management programme for patients without contraindications to exercise
Number of subjects: 212
Study: 27055521

Group type: EXPERIMENTAL
Intervention: GSK2586184 (50-400 mg, oral, twice daily for 12 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (oral, twice daily for 12 weeks)
Number of subjects: 50
Study: 25090449

Group type: EXPERIMENTAL
Intervention: Value-affirmation
Number of subjects: 55

Group type: COMPARATOR
Intervention: Non-affirmation control
Number of subjects: 55
Study: 22808706

Group type: EXPERIMENTAL
Intervention: Random practice with target changes in the vertical axis
Number of subjects: 24

Group type: COMPARATOR
Intervention: Blocked practice with target changes in the horizontal axis
Number of subjects: 24
Study: 20575704

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (single dose)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Physiologic saline (placebo)
Number of subjects: 100
Study: 18474451

Group type: EXPERIMENTAL
Intervention: Effleurage massage therapy (20 min of effleurage on ten occasions)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control visits (ten 20-minute visits)
Number of subjects: 22
Study: 15598944

Group type: EXPERIMENTAL
Intervention: docetaxel 75 mg/m(2) every 3 weeks (Dq3w)
Number of subjects: 125

Group type: COMPARATOR
Intervention: docetaxel 40 mg/m(2) given weekly for 6 weeks followed by 2 weeks of rest (Dqw)
Number of subjects: 125
Study: 11781120

Group type: EXPERIMENTAL
Intervention: OQLQ (Osteoporosis Quality of Life Questionnaire)
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: QUALEFFO (Quality of Life Questionnaire for Patients with Osteoporosis)
Number of subjects: 338

Group type: COMPARATOR
Intervention: SF-36 (common anchor test)
Number of subjects: 338
Study: 9843762

Group type: EXPERIMENTAL
Intervention: Loxiglumide (10 mg/kg/h)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 0
Study: 7866080

Group type: EXPERIMENTAL
Intervention: Homoeopathic medicines
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study: 2680794

Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg orally
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31760524

Group type: EXPERIMENTAL
Intervention: Second TUR
Number of subjects: 210
Study: 30827975

Group type: EXPERIMENTAL
Intervention: Greater perceived importance of ethnic identity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ability to speak tribal language
Number of subjects: 0
Study: 28008145

Group type: EXPERIMENTAL
Intervention: High BRCA1 expression (n = 221)
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: Low MSH2 expression (n = 356)
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: Low BRCA1 and high MSH2 (n = 55)
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: Intermediate risk group (n = 82)
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: High BRCA1 and low MSH2 (n = 67)
Number of subjects: 528
Study: 25982539

Group type: EXPERIMENTAL
Intervention: Secukinumab retreatment as needed (300 mg)
Number of subjects: 966

Group type: EXPERIMENTAL
Intervention: Secukinumab retreatment as needed (150 mg)
Number of subjects: 966

Group type: COMPARATOR
Intervention: Secukinumab fixed interval (300 mg)
Number of subjects: 966

Group type: COMPARATOR
Intervention: Secukinumab fixed interval (150 mg)
Number of subjects: 966
Study: 23551359

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol 160/4.5 μg two inhalations twice daily via Turbuhaler®
Number of subjects: 1293

Group type: COMPARATOR
Intervention: Formoterol 4.5 μg two inhalations twice daily via Turbuhaler®
Number of subjects: 1293
Study: 21337428

Group type: EXPERIMENTAL
Intervention: Kyphoplasty
Number of subjects: 300

Group type: COMPARATOR
Intervention: Nonsurgical therapy
Number of subjects: 300
Study: 19708000

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Eprosartan 600 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 17633357

Group type: EXPERIMENTAL
Intervention: Sequential Colon Dialysis (SCD)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Peritoneal Dialysis (PD)
Number of subjects: 293

Group type: COMPARATOR
Intervention: Control (SCD, HD, PD)
Number of subjects: 293
Study: 15041005

Group type: EXPERIMENTAL
Intervention: Sleep educational program (2-hour interactive course)
Number of subjects: 540

Group type: COMPARATOR
Intervention: Control group (no educational program)
Number of subjects: 540
Study: 11249162

Group type: EXPERIMENTAL
Intervention: Early tactile stimulation (Group 1)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (Group 2)
Number of subjects: 49
Study: 9515561

Group type: EXPERIMENTAL
Intervention: L-NMMA (3 mg/kg bolus over 5 minutes followed by continuous i.v. infusion of 50 microg/kg/min over 75 minutes)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 8070302

Group type: EXPERIMENTAL
Intervention: Simvastatin for 6 months
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 70
Study: 29929945

Group type: EXPERIMENTAL
Intervention: Logistic regression classifier
Number of subjects: 10785

Group type: EXPERIMENTAL
Intervention: Support Vector Machine (SVM) classifier
Number of subjects: 10785

Group type: EXPERIMENTAL
Intervention: Random forest classifier
Number of subjects: 10785

Group type: COMPARATOR
Intervention: Baseline ZeroR algorithm
Number of subjects: 10785
Study: 26795426

Group type: EXPERIMENTAL
Intervention: Intensive psychotherapy for depression (n=141)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Brief psychoeducational intervention (n=111)
Number of subjects: 252
Study: 24326967

Group type: EXPERIMENTAL
Intervention: Deep sclerectomy with mitomycin C 0.2 mg/mL
Number of subjects: 87

Group type: COMPARATOR
Intervention: Trabeculectomy with mitomycin C 0.2 mg/mL
Number of subjects: 87
Study: 22117083

Group type: EXPERIMENTAL
Intervention: Automated Office Blood Pressure (AOBP) measurement
Number of subjects: 461

Group type: COMPARATOR
Intervention: Manual Office Blood Pressure (MOBP) measurement
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Comparison of AOBP and MOBP to Awake Ambulatory Blood Pressure (AABP)
Number of subjects: 461
Study: 20420104

Group type: EXPERIMENTAL
Intervention: 3 eggs per week
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: 10 eggs per week
Number of subjects: 417
Study: 18308687

Group type: EXPERIMENTAL
Intervention: Heart Failure (HF) hospitalization
Number of subjects: 11040

Group type: EXPERIMENTAL
Intervention: Predictors of HF
Number of subjects: 11040

Group type: EXPERIMENTAL
Intervention: Risk of death due to HF
Number of subjects: 11040
Study: 16444435

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg/day, for 12 weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 24
Study: 12859311

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 1.5 mg/ml, 10 ml/h (n = 26)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 5 mg/ml, 3 ml/h (n = 33)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 7.5 mg/ml, 2 ml/h (n = 31)
Number of subjects: 90
Study: 10624999

Group type: EXPERIMENTAL
Intervention: remifentanil-propofol
Number of subjects: 60

Group type: COMPARATOR
Intervention: desflurane
Number of subjects: 60

Group type: COMPARATOR
Intervention: sevoflurane
Number of subjects: 60
Study: 9179120

Group type: EXPERIMENTAL
Intervention: Pyloroplasty
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Pyloromyotomy
Number of subjects: 92
Study: 8252957

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Captopril (50 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 14
Study: 3900393

Group type: EXPERIMENTAL
Intervention: Diflunisal high dose (1000 mg daily)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Diflunisal low dose (750 mg daily)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Diflunisal (both doses)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Diflunisal high dose vs low dose
Number of subjects: 227
Study: 30615231

Group type: EXPERIMENTAL
Intervention: Metformin 1g
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 10
Study: 29573224

Group type: EXPERIMENTAL
Intervention: Mediterranean diet for 3 years
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Low-fat diet for 3 years
Number of subjects: 1002
Study: 27480654

Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine 10 ml (Group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.25% ropivacaine 20 ml (Group B)
Number of subjects: 60
Study: 25766415

Group type: EXPERIMENTAL
Intervention: Everolimus (5-10 mg/day)
Number of subjects: 15
Study: 22093109

Group type: EXPERIMENTAL
Intervention: Synbiotics treatment
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: High fecal HBD2 levels at 6 months
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: High fecal HNP1-3 levels at 6 months
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Very low or high HBD2 levels at 6 months
Number of subjects: 102
Study: 20407630

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Post hoc analyses
Number of subjects: 0
Study: 17879544

Group type: EXPERIMENTAL
Intervention: Zhongfu Hypotension Capsule (ZHC) - 3 capsules (0.5 g/capsule) twice a day for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lotensin Tablet - 1 tablet (10 mg/tab.) once a day for 4 weeks
Number of subjects: 0
Study: 15730353

Group type: EXPERIMENTAL
Intervention: Active medications (specific medications not detailed)
Number of subjects: 357

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Active medications and Placebo
Number of subjects: 357
Study: 12142119

Group type: EXPERIMENTAL
Intervention: HERG K897T polymorphism (genotypes AC or CC)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Genotype AA
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: HERG K897T polymorphism (in females)
Number of subjects: 187
Study: 10442116

Group type: EXPERIMENTAL
Intervention: Artemisinin
Number of subjects: 65

Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 65
Study: 7540606

Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with Mitomycin C and Bleomycin (group B)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Radiotherapy alone (group A)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with Mitomycin C and Bleomycin (group B) in oropharyngeal carcinoma
Number of subjects: 49

Group type: COMPARATOR
Intervention: Radiotherapy alone (group A) in oropharyngeal carcinoma
Number of subjects: 49
Study: 2334326

Group type: EXPERIMENTAL
Intervention: Tono-Pen
Number of subjects: 50

Group type: COMPARATOR
Intervention: Pneumotonometer
Number of subjects: 50

Group type: COMPARATOR
Intervention: Manometer
Number of subjects: 50
Study: 375433

Group type: EXPERIMENTAL
Intervention: Gentamicin and penicillin (60 mg/m2/8 h)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gentamicin (in patients with renal failure)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gentamicin (constant vs intermittent infusion)
Number of subjects: 0
Study: 31640314

Group type: EXPERIMENTAL
Intervention: Gflex+plyo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Gflex
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Gplyo
Number of subjects: 34

Group type: COMPARATOR
Intervention: Gcon
Number of subjects: 34
Study: 30447045

Group type: EXPERIMENTAL
Intervention: Ureteric stent removal by string
Number of subjects: 149

Group type: COMPARATOR
Intervention: Ureteric stent removal by cystoscope
Number of subjects: 149
Study: 27884804

Group type: EXPERIMENTAL
Intervention: Flexible duty hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: Female PGY2 to 3 residents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Female PGY4 to 5 residents
Number of subjects: 0